Skip to main content
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis logoLink to Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
. 2016 Sep-Oct;36(5):574–575. doi: 10.3747/pdi.2015.00287

Shewanella algae Peritonitis in Patients on Peritoneal Dialysis

Malini Shanmuganathan 1, Bak Leong Goh 1, Christopher Lim 2,*, Zakaria NorFadhlina 2, Ibrahim Fairol 1
PMCID: PMC5033638  PMID: 27659933

Abstract

Patients with peritonitis present with abdominal pain, diarrhea, fever, and turbid peritoneal dialysis (PD) fluid. Shewanella algae peritonitis has not yet been reported in PD patients in the literature. We present the first 2 cases of Shewanella algae peritonitis in PD patients. Mupirocin cream is applied on the exit site as prophylactic antibiotic therapy.

Keywords: Peritonitis, shewanella

Case Report 1

A 64-year-old man on weekly cycler peritoneal dialysis (PD) presented with abdominal pain and diarrhea preceded by 2 days of fever and lethargy. Empirical intraperitoneal (IP) cloxacillin 250 mg quater in die (qid) and ceftazidime 250 mg qid was initiated. Turbid PD fluid showed numerous gram-negative rods, white blood cell (WBC) of 450 cells/mm3 (majority polymorphs). Culture revealed Shewanella algae in aerobic BACTEC blood culture bottle (BD, Franklin Lakes, NJ, USA) and in PD fluid, sensitive to ceftazidime, amikacin, gentamicin, and piperacillin but resistant to imipenem and ciprofloxacin. Intraperitoneal medication was switched to IV ceftazidime, and IV gentamicin was initiated in view of septicemia and elevated blood WBC. Infection resolved completely after 14 days of treatment, without removal of the catheter, and there was no recurrence of peritonitis.

Case Report 2

A 54-year-old man on continuous ambulatory PD (CAPD) for 2 years presented with cloudy PD fluid, abdominal pain preceded by 3 days of reduced appetite, fever, and lethargy. Intraperitoneal cloxacillin 250 mg qid and IP ceftazidime 250 mg qid was initiated. Dialysate WBC was 250 cells/mm3 (majority polymorphs). Following rapid deterioration, he succumbed within 48 hours of admission. His peritoneal catheter exit site grew Staphylococcus aureus and Corynebacterium sp. Peritoneal dialysis fluid culture revealed Shewanella algae, sensitive to imipenem, meropenem, gentamicin, amikacin, and piperacillin/tazobactam. Blood WBC was 10.5 × 109/L and blood culture revealed no growth.

Discussion

Shewanella spp are hydrogen sulphide-producing motile gram-negative bacilli, first described in 1931(1). Isolated from putrefied butter and water supplies in dairies, this species was initially named Achromobacter putrefaciens (1). James Shewan then went on to reclassify this genus as Group IV Pseudomonas (2). Eventually in 1985, phylogenetic studies by Mac Donell and Colwell led to the reclassification of this genus under Vibrionaecea and a new genus for these organisms, Shewanella spp, in honour of James Shewan. Following the discovery of a tetrodotoxin producing Shewanella isolate from red algae, Shewanella algae was initially proposed as a new species in 1990 (3). Out of more than 30 known species of Shewanella, S. putrefaciens and S. algae are the only Shewanella spp isolated in humans (4,5). Nitrite-reducing ability and production of mucoid colonies with beta-hemolysis on sheep blood agar distinguishes these 2 species from each other. Unlike S. putrefaciens, S. algae is unable to produce acid from maltose, sucrose, or L-arabinose (6). Its ability to produce beta-hemolytic substance is the reason S. algae has been proposed to be more pathogenic than S. putrefaciens.

To the best of our knowledge, there have been 12 reported cases of S. Algae infections, mostly involving soft tissue infection. There have been 6 reported cases of CAPD peritonitis caused by S. putrefaciens (710). Shewanella bacteraemia in hemodialysis was reported in 5 cases, 2 caused by S. algae, 3 caused by S. putrefaciens.

In our hospital, identification of the bacteria involved putting the medium into selective growth in an aerobic environment, and then using an automated microbial identification system to identify the microorganism. Our first patient appeared to have resistance to imepenem according to the antibiotic sensitivity report from our laboratory. Resistance to carbapenem has also been described in 2 other cases elsewhere. This resistance is thought to be due to a carbepenem-hydrolyzing ability mediated by chromosome encoded beta-lactamase gene OXA-55 in a known carbapenem-resistant strain of S. algae KB-1. Resistance to the quinolone group of antibiotics appears to be predominantly plasmid-mediated by QnrA determinants in Shewanella algae found in nature (11,12). Our second patient lived in one of the largest ex-mining communities, raising suspicion that exposure to mining water and minerals could have been the route of infection. He succumbed within 48 hours of presentation. His strain of S. algae may have been more virulent. Furthermore, concomitant infections on board could have compounded the severity of peritonitis that led to his untimely demise. The estimated route of infection in the first case remains unclear as the details were not documented.

Conclusion

We encountered 2 extreme outcomes with our 2 cases, 1 person surviving and the other succumbing to infection. Although Shewanella peritonitis is rare, its pathogenic potential must not be underestimated. Our first case demonstrated that Shewanella algae peritonitis can be treated with antibiotic without removal of the catheter despite the propensity of this organism to form biofilms. The organism may be naturally carbapenem- and quinolone-resistant and either antibiotics should not be the first choice when treating this organism. Our second case highlights the need to raise suspicion of Shewanella infection in patients living in environments surrounded by any form of water source.

Disclosures

The authors have no financial conflicts of interest to declare.

Acknowledgments

We thank Dr. YM Ganeshadeva for his valuable contribution to the case report.

REFERENCES

  • 1. Derby HA, Hammer HA. Bacteriology of butter. IV: Bacteriological studies on surface taint butter. Iowa Agric Exp Station Res Bull 1931; 145:389–416. [Google Scholar]
  • 2. Shewan JM, Hobbs G, Hodgkiss W. A determinative scheme for the identification of certain genera of gram-negative bacteria, with special reference to the Pseudomonadaceae. J Appl Bacteriol 1960; 23: 379–90. [Google Scholar]
  • 3. Simudu UK, Kita-Tsukamoto T, Yasumoto, Yotsu M. Taxonomy of four marine bacterial strains that produce tetrodotoxin. Int J Syst Bacteriol 1990; 40:331–6. [DOI] [PubMed] [Google Scholar]
  • 4. Nozue H, Hayashi T, Hashimoto Y, Ezaki T, Hamaski K, Ohwada K, et al. Isolation and characterization of Shewanella alga from human clinical specimens and emendation of the description of S. alga Simidu et al., 1990, 335. Int J Syst Bacteriol 1992; 42:628–34. [DOI] [PubMed] [Google Scholar]
  • 5. Khashe S, Janda JM. Biochemical and pathogenic properties of Shewanella alga and Shewanella putrefaciens. J Clin Microbiol 1998; 36:783–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Holt HM, Gahrn-Hansen B, Bruun B. Shewanella algae and Shewanella putrefaciens: clinical and microbiological characteristics. Clin Microbiol Infect 2005; 11: 347–52. [DOI] [PubMed] [Google Scholar]
  • 7. Yim SY, Kang YS, Cha DR, Park DW, Youn YK, Jo YM, et al. Fatal PD peritonitis, necrotizing fasciitis, and bacteremia due to Shewanella putrefaciens. Perit Dial Int 2010; 30(6):667–9. [DOI] [PubMed] [Google Scholar]
  • 8. Bhandari S, Pan TL, Horvath J, Tiller D. CAPD, swimming in Shewanella. Nephrol Dial Transplant 2000; 15(9):1484–5. [DOI] [PubMed] [Google Scholar]
  • 9. Dan M, Gutman R, Biro A. Peritonitis caused by P. putrefaciens in patients undergoing continuous ambulatory PD. Clin Infect Dis 1992; 14:359–60. [DOI] [PubMed] [Google Scholar]
  • 10. Vickers JA, Ullian ME. Recurrent Shewanella putrefacians peritonitis in a chronic peritoneal dialysis patient. Dial Transplant 2011; 168–70. [Google Scholar]
  • 11. Kim DM, Kang CI, Lee CS, Kim HB, Kim EC, Kim NJ, et al. Treatment failure due to emergence of resistance to carbapenem during therapy for Shewanella algae bacteremia. J Clin Microbiol 2006; 44(3):1172–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Heritier C, Poirel L, Nordmann P. Genetic and biochemical characterization of a chromosome-encoded carbapenem-hydrolyzing ambler class D beta-lactamase from Shewanella alga. Antimicrob Agents Chemother 2004; 48:1670–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Chang CF, Chen TL, Chen TW, Yang WC, Lin CC. Recurrent dialysis associated Aeromonas hydrophilia peritonitis: reports of 2 cases and review of the literature. Perit Dial Int 2005; 25:496–9. [PubMed] [Google Scholar]

Articles from Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis are provided here courtesy of Multimed Inc.

RESOURCES